23rd annual report: Top 100 medicine highlights PharmaLive (press release) (subscription) Roche reported Rituxan/MabThera (rituximab) sales of SFr1.7 billion during first-quarter 2013, up 6 percent compared to 1Q 2012. Sales improved due to increased use of the drug in the first-line maintenance treatment of follicular lymphoma, a type of ... |
